HIT is an immune-mediated condition, characterized by platelet drop of 50% or greater, typically within 5 to 10 days of exposure to heparin, leading to hypercoagulability and presence of platelet-activating IgG antibodies.4-6 These antibodies target complexes of PF4 and heparin.6 The IgG-PF4-heparin immune complexes cross-link Fcy (γ) receptors on platelets and monocytes and activate them. Activation of platelets and monocytes increases thrombin generation, leading to thromboembolic complications.4